THE ROLE OF ANGIOTENSINOGEN (AGT) IN ATHEROSCLEROTIC RENAL ARTERY DISEASE

dc.contributor.author	Nazarova N.O
dc.date.accessioned	2026-06-09T08:39:40Z
dc.date.available	2026-06-09T08:39:40Z
dc.date.issued	2026
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/4162
dc.description.abstract	Atherosclerotic renal artery disease (ARAD) is a major cause of secondary hypertension and ischemic nephropathy. Angiotensinogen (AGT), as the precursor of angiotensin peptides in the renin-angiotensin-aldosterone system (RAAS), is central to many of the pathophysiologic mechanisms in ARAD. In this review, we examine clinical studies on AGT gene polymorphisms, outcomes of RAAS blockade, and the impact of AGT-fo cused therapies in ARAD. The aim is to clarify what is known, what remains controversial, and which areas merit further investigation	en_US
dc.language.iso	en_US	en_US
dc.publisher	O'zbekiston, Toshkent ( O‘ZBEKISTON TIBBIYOT AXBOROTNOMASI JURNALI )	en_US
dc.subject	chronic kidney disease, renal artery atherosclerosis, urea, creatinine, cystatin C, endothelin1, proteinuria	en_US
dc.title	THE ROLE OF ANGIOTENSINOGEN (AGT) IN ATHEROSCLEROTIC RENAL ARTERY DISEASE	en_US
dc.type	Article	en_US